https://nl.marketscreener.com/koers/aandeel/EISAI-CO-LTD-6492461/nieuws/Eisai-presenteert-resultaten-van-fase-3-bevestigende-Clarity-AD-studie-met-Lecanemab-voor-de-vroege-42464395/?utm_source=telegram&utm_medium=social&utm_campaign=share